Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Xi'an Xintong Medicine Research Co. Ltd. has synthesized 1,3-benzodioxolane-containing compounds acting as dual Bruton tyrosine kinase (BTK) and tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis and B-cell lymphoma.
RNA binding fox-1 homologue 1 (RBFOX1) is a splicing factor that regulates alternative splicing and modulates the expression of several genes involved in brain development, and it is among the top identified loci related to psychiatric disorders.
Rational drug design based on EPI-X4, endogenous antagonist of C-X-C motif chemokine receptor (CXCR4), led to the identification of optimized analogues named JMF-01 to JMF-07, which demonstrated increased antagonistic activity.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS).
The British Columbia Cancer Agency recently discussed their research efforts toward the discovery of new radiotherapeutic agents for the treatment of prostate cancer.
At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza.
Standigm Inc. has identified new phenylaminopyrimidine leucine-rich repeat kinase 2 (LRRK2; Dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment neurodegeneration, among other disorders.
RSS
